Celsion Corp. has signed a long-term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox, Celsion’s heat-activated liposomal encapsulation of doxorubicin. The agreement will initially be limited to China, with Hisun retaining an option for global supply after local regulatory approvals in China. Hisun will collaborate with Celsion for the regulatory approval of ThermoDox in China. “Our partnership with Hisun serves multiple strategic purposes...